Javelin Pharmaceuticals, Inc. (NYSE:JAV) has scheduled a Special Meeting of Stockholders on April 22, 2010. The meeting will be held to vote on the adoption and approval of the proposed merger agreement with Myriad Pharmaceuticals, Inc. Javelin stockholders as of March 8, 2010 will be able to attend and vote, or vote by proxy at the meeting.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
The Meeting will take place at 150 CambridgePark Drive, in Cambridge, Massachusetts. It will begin at 2:00 pm ET. Once approved, the merger will take place soon after the meeting. The merger is subject to the satisfaction of closing conditions discussed in the joint proxy statement/prospectus.
Javelin Pharmaceuticals, Inc. (Javelin) is a specialty pharmaceutical company that applies technologies to develop new products and improved formulations of existing drugs that target medical need in the pain management market. The Company's product candidates are focused on treating an array of pain disorders ranging from acute and episodic moderate-to-severe pain associated with cancer pain, post-operative pain, post-trauma pain, such as orthopedic injury pain, procedural pain and burn pain. The Company’s products include Dyloject (injectable diclofenac), Ereska (intranasal ketamine, formerly PMI-150) and Rylomine (intranasal morphine).
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
